Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1959)	10/11/2007 2:58:51 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

NPSP tanked today after reporting results of its PIII on patients with SBS. bigcharts.marketwatch.com 46% of patients receiving the lower dose of GATTEX responded and achieved an statistically significant reduction in PN compared to placebo (p=0.007), but 25% of patients that received the higher dose didn't reach statistical significant results.<g> However,in view of the results with the lower dose & the drug's orphan designation in SBS, NPSP plans to meet with the FDA "to discuss the path to regulatory approval for GATTEX".<g> The stock tried to rally some after the initial DG, but it seems that it will close near its intraday Ls, albeit probably above its Aug 16 L of 3.58 bigcharts.marketwatch.com Bernard